A cryptic Federal Register notice published in early September has ignited a firestorm of scrutiny among medical experts, defense analysts, and government oversight advocates. The notice, which initially appeared vague regarding the specific medical countermeasures it addressed, has now been linked to an aggressive, accelerated pathway for a proprietary sublingual ketamine product, "Wafermine," produced by the Singapore-based firm iX Biopharma.
The administrative actions—taken in tandem by the Department of Defense (DoD) and the Department of Health and Human Services (HHS)—have bypassed traditional competitive procurement norms, raising fundamental questions about the intersection of emergency military preparedness, private corporate interests, and the integrity of the FDA’s regulatory oversight.
The Chronology of an Accelerated Pathway
The sequence of events leading to the current controversy began in mid-summer, setting a rapid pace that has left many in the military medical community struggling to keep up with the policy shifts.
- July 2026: Secretary of Defense Pete Hegseth issued a formal determination citing a "military emergency—or significant potential for one—involving a higher risk of a chemical, biological, radiological, or nuclear (CBRN) attack on U.S. forces." This determination provided the legal bedrock for invoking extraordinary executive powers regarding medical countermeasures.
- August 2026: HHS Secretary Robert F. Kennedy Jr. issued a corresponding determination, declaring that circumstances existed to justify the emergency use of specific medical countermeasures—specifically, treatments for moderate-to-severe acute pain resulting from such high-stakes battlefield environments.
- September 3, 2026: The Federal Register officially posted the notice of these declarations, though the language remained generalized, causing immediate confusion within the defense health community.
- September 2026 (Mid-month): iX Biopharma issued a press release clarifying that the U.S. government had cleared an emergency use pathway specifically for its sublingual ketamine product, Wafermine.
The revelation that this specific product was the target of these broad executive declarations has drawn intense criticism, particularly given that the product is currently the subject of an ongoing Phase III clinical trial partially funded by a $41 million sole-source contract awarded earlier this year.
The $41 Million "Bizarre" Arrangement
The financial architecture of this deal is perhaps the most contentious element of the story. The $41 million contract, awarded to iX Biopharma by the Trump-led DoD, was not the result of a competitive bidding process. Instead, it was classified as an "Other Transaction Agreement" (OTA).
OTAs are designed to provide the military with the agility to collaborate with commercial entities for research and prototype development. While these agreements offer flexibility, federal guidelines mandate that competitive procedures should be employed wherever possible. Critics argue that the nature of this award—given without an open solicitation—lacks the transparency required for such a significant taxpayer expenditure.
"The accelerated Emergency Use Authorization (EUA) strategy and sole-source award deserve transparency and scrutiny," said Terry Adirim, MD, MPH, MBA, former acting assistant secretary of defense for health affairs. "This contract came out of the blue, and many in the sector find the arrangement, at best, bizarre."
Medical Utility vs. Regulatory Shortcuts
From a clinical perspective, the military’s interest in a portable, needle-free ketamine delivery system is not inherently illogical. Ketamine has long been a staple of Tactical Combat Casualty Care (TCCC). Unlike traditional opioids, which can cause dangerous respiratory depression and hypotension—a fatal combination for soldiers suffering from hemorrhagic shock—ketamine maintains a more favorable hemodynamic profile.
However, Dr. Adirim and other experts emphasize a critical distinction: while intravenous, intramuscular, and intranasal ketamine are well-vetted, the sublingual "wafer" formulation remains an experimental, proprietary technology.
"There may be legitimate operational reasons for wanting to use it," Adirim noted. "Sublingual delivery is easy to carry, and it is needle-free, which is a massive advantage in large-scale combat. But those reasons should be clearly explained to the public and the medical community. Furthermore, why does this specific drug need to move through an emergency use pathway before the normal Phase III studies and approval process are complete?"
The concern is that the EUA pathway may be used to bypass the final, most rigorous stages of safety and efficacy testing. Because sublingual absorption is different from intravenous delivery, the dosage requirements and metabolic rates for the wafer could vary significantly, necessitating the very data that the ongoing Phase III trial is intended to provide.
Implications for Regulatory Integrity
The Federal Register notice does not automatically grant an EUA; it merely establishes the legal mechanism for iX Biopharma to apply for one. The final decision rests with the FDA, which must determine whether the product meets the statutory standards for an EUA under the declared emergency conditions.
"The FDA still has to review the application and decide whether it meets the statutory standard," Adirim explained. "But the pressure of an executive-level emergency declaration can complicate the regulatory environment."
This is only the second time in history that this specific HHS/DoD collaborative pathway has been invoked. The first instance occurred in 2018, during the first Trump administration, regarding the distribution of freeze-dried plasma for combat-related hemorrhaging. In that instance, the medical need was considered dire and universally accepted by the military medical community. Critics argue that the current situation, which involves a pre-revenue company seeking to secure market access before completing its Phase III clinical trials, lacks the same level of objective, life-saving urgency.
Geopolitical Tensions and Strategic Readiness
Questions remain regarding the underlying "military emergency" cited by Secretary Hegseth. While the memo specifically mentions the risk of CBRN attacks, some observers are questioning if the urgency is linked to broader intelligence regarding the escalation of conflicts, potentially involving regional powers such as Iran.
The lack of a transparent link between the threat assessment and the specific solution—a proprietary, non-competitively sourced drug—has fueled speculation. As of the time of publication, the Department of Health and Human Services had not responded to requests for comment regarding the justification for the emergency declaration or the selection of Wafermine as the primary countermeasure.
The Road Ahead: Revenue vs. Rigor
For iX Biopharma, the stakes are high. The company has stated in its public disclosures that it plans to complete its EUA submission by the end of 2026. Should the FDA grant the authorization, it would allow the company to distribute the product to the military immediately, effectively generating revenue before the conclusion of their standard FDA approval process.
For the U.S. military, the path forward is more complex. The reliance on non-competitive, proprietary, and potentially under-tested medical technology poses a long-term risk to supply chain resilience and clinical safety. If the military integrates Wafermine into its standard issue kits, it commits itself to a single vendor for a critical pain management tool.
As the scientific community awaits the results of the ongoing Phase III study, the broader implications remain: Does the "emergency" designation provide a legitimate, agile solution for the warfighter, or is it a convenient mechanism for bypassing the regulatory and competitive hurdles that protect both the soldier and the taxpayer?
Until the DoD provides a full accounting of the operational necessity and the legal justification for the sole-source award, the "bizarre" nature of this emergency authorization will likely continue to draw sharp rebuke from those who believe that military medical readiness should be built on a foundation of open competition, rigorous science, and transparent oversight.
